LP-10 Update

Lipella Pharmaceuticals Inc is dedicated to improving the lives of cancer survivors with the development of innovative products for the treatment of collateral damage caused by chemotherapy and radiation therapy.

Orphan Indication: Most recently, Lipella has received US FDA IND approval for for its phase-2a clinical trial studying the safety and efficacy of LP-10 for hemorrhagic cystitis.

Learn more about our pipeline.